Vox Markets Logo

Powerhouse Energy, Futura Medical and Chris Bailey

11:51, 18th April 2019
Justin Waite
Daily Podcast with Justin Waite
TwitterFacebookLinkedIn

Vox Media Player

 

DYOR Disclaimer

If you find this podcast useful please give it a rating and review on iTunes by clicking here

Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app


On today's Vox Markets Podcast: Powerhouse Energy, Futura Medical and Chris Bailey

David Ryan, Chief Executive Officer of PowerHouse Energy (PHE) FOLLOW discusses the significance of their first revenue generating contract.

PowerHouse Energy has developed a proprietary process technology - DMG® - which can utilise waste plastic, end-of-life-tyres, and other waste streams to efficiently and economically convert them into syngas from which valuable products such as chemical precursors, hydrogen, electricity and other industrial products may be derived. The PowerHouse technology is one of the world’s first proven, modular, hydrogen from waste (HfW) process. The PowerHouse DMG® process can generate in excess of 1 tonne of road-fuel quality H2, and more than 28MW/h of exportable electricity per day. The PowerHouse process produces low levels of safe residues and requires a small operating footprint, making it suitable for deployment at enterprise and community level.


James Barder, Chief Executive Officer of Futura Medical (FUM) FOLLOW talks about their lead drugs, their progress and milestones approaching.

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

(Interview starts at 14 minutes 7 seconds)


Chris Bailey founder of Financial Orbit covers:

Unilever (ULVR) FOLLOW

Polymetal (POLY) FOLLOW

PZ Cussons (PZC) FOLLOW

(Interview starts at 25 minutes 48 seconds)

TwitterFacebookLinkedIn

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Recent Articles
Watchlist